MCID: CNS004
MIFTS: 56

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 42 44 15 32

Classifications:



External Ids:

Disease Ontology 12 DOID:2089
ICD9CM 34 564.0
MeSH 44 D003248
NCIt 50 C37930
SNOMED-CT 67 363693003
ICD10 32 K59.0
UMLS 70 C0009806

Summaries for Constipation

MedlinePlus : 42 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to irritable bowel syndrome and hirschsprung disease 1. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Acetaminophen and Hydromorphone have been mentioned in the context of this disorder. Affiliated tissues include colon, spinal cord and breast, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 73 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 733)
# Related Disease Score Top Affiliating Genes
1 irritable bowel syndrome 32.9 VIP TAC1 SST SLC6A4 PYY MLN
2 hirschsprung disease 1 32.6 VIP TAC1 RET KIT GDNF CALCA
3 intestinal pseudo-obstruction 32.5 VIP SST RET MLN KIT FLNA
4 intestinal obstruction 32.3 RET MLN KIT GDNF FLNA
5 central hypoventilation syndrome, congenital 32.2 TACR1 TAC1 RET GDNF
6 neurogenic bowel 32.2 VIP TAC1 MLN
7 hypoganglionosis 32.2 RET GDNF
8 volvulus of midgut 32.2 SST PYY MLN
9 eating disorder 32.1 SLC6A4 PYY OPRM1 CCK
10 diarrhea 31.9 TAC1 SST SLC6A4 PYY MLN CCK
11 megacolon 31.7 VIP RET GDNF
12 ileus 31.6 VIP SST OPRM1 MLN CCK CALCA
13 anismus 31.5 VIP TAC1 CLCN2
14 gastroesophageal reflux 31.3 VIP PYY MLN CCK
15 pain agnosia 31.3 TACR1 TAC1 OPRM1 CCK CALCA
16 gastroparesis 31.2 SST MLN CCK
17 achalasia 31.1 VIP RET KIT GDNF
18 carcinoid syndrome 31.1 SST PYY CALCA
19 paralytic ileus 31.1 VIP TAC1 MLN
20 headache 31.1 TAC1 SLC6A4 CCK CALCA
21 colonic pseudo-obstruction 31.0 SST MLN HTR4
22 vesicoureteral reflux 1 31.0 RET GDNF EBF3
23 multiple endocrine neoplasia 30.9 VIP SST RET GDNF CALCA
24 migraine with or without aura 1 30.8 VIP TACR1 TAC1 SLC6A4 PPOX OPRM1
25 neurogenic bladder 30.7 TACR1 TAC1 EBF3
26 gastroenteritis 30.7 PYY MLN CALCA
27 multiple endocrine neoplasia, type iib 30.7 RET GDNF CALCA
28 fibromyalgia 30.7 TACR1 SLC6A4 OPRM1 CALCA
29 rare tumor 30.6 SST RET KIT
30 neuroma 30.6 RET GDNF CALCA
31 ganglioneuroma 30.6 VIP SST RET
32 duodenal ulcer 30.6 SST MLN CCK
33 pheochromocytoma 30.6 VIP SST RET MLN KIT GDNF
34 somatoform disorder 30.5 TACR1 TAC1 SLC6A4 OPRM1 CALCA
35 peripheral nervous system disease 30.5 TAC1 SST KIT GDNF CALCA
36 dumping syndrome 30.4 SST PYY MLN CCK
37 serotonin syndrome 30.4 TAC1 SST SLC6A4 PYY
38 neuronal intestinal dysplasia, type b 30.4 RET KIT
39 cystitis 30.4 TACR1 TAC1 KIT GDNF
40 gallbladder disease 30.4 SST PYY MLN CCK
41 thyroid gland medullary carcinoma 30.4 SST RET GDNF CALCA
42 thyroid carcinoma, familial medullary 30.4 SST RET GDNF CCK CALCA
43 panic disorder 30.3 TACR1 TAC1 SLC6A4 CCK
44 functional colonic disease 30.3 SST MLN
45 paraganglioma 30.3 SST RET KIT CALCA
46 paine syndrome 30.3 TACR1 TAC1 SLC6A4 OPRM1 CALCA
47 somatization disorder 30.3 TAC1 SLC6A4
48 attention deficit-hyperactivity disorder 30.3 TACR1 SLC6A4 OPRM1 HTR4 GDNF
49 neuroendocrine carcinoma 30.3 SST KIT CALCA
50 biliary dyskinesia 30.3 SST CCK

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

MGI Mouse Phenotypes related to Constipation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 CCK CLCN2 FLNA GDNF HTR4 KIT
2 homeostasis/metabolism MP:0005376 9.97 CCK CLCN2 FLNA HTR4 KIT OPRM1
3 digestive/alimentary MP:0005381 9.91 CLCN2 FLNA GDNF KIT OPRM1 PPOX
4 nervous system MP:0003631 9.8 CCK CLCN2 EBF3 FLNA GDNF HTR4
5 normal MP:0002873 9.28 FLNA KIT OPRM1 PYY RET SLC6A4

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Methadone Approved Phase 4 76-99-3 4095
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
10
Orphenadrine Approved Phase 4 83-98-7 4601
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
13
Lactulose Approved Phase 4 4618-18-2 11333
14
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
15
Turmeric Approved, Experimental, Investigational Phase 4
16
Alvimopan Approved, Investigational Phase 4 156053-89-3 5488548
17
Ondansetron Approved Phase 4 99614-02-5 4595
18
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
19
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
20
Tapentadol Approved Phase 4 175591-23-8 9838022
21
Magnesium oxide Approved Phase 4 1309-48-4 14792
22
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
23
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
24
Coal tar Approved Phase 4 8007-45-2
25
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
26
Sorbitol Approved Phase 4 50-70-4 5780
27
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
28
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
29
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
30
Ethanol Approved Phase 4 64-17-5 702
31
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
32
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
33
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
34
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
35
Linaclotide Approved Phase 4 851199-59-2 65351
36
Naloxegol Approved Phase 4 854601-70-0
37
Loperamide Approved Phase 4 53179-11-6 3955
38
Bisacodyl Approved Phase 4 603-50-9
39
Pancrelipase Approved, Investigational Phase 4 53608-75-6
40
Sodium citrate Approved, Investigational Phase 4 68-04-2
41
Magnesium citrate Approved Phase 4 3344-18-1
42
Baclofen Approved Phase 4 1134-47-0 2284
43
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
44
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
47 abobotulinumtoxinA Phase 4
48 Botulinum Toxins, Type A Phase 4
49 Cholinergic Agents Phase 4
50 Parasympatholytics Phase 4

Interventional clinical trials:

(show top 50) (show all 806)
# Name Status NCT ID Phase Drugs
1 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
2 The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial Unknown status NCT01388712 Phase 4
3 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
4 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
5 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
6 Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal fissure in Children Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
7 Comparative Study Between Botulinum Toxin Injection and Myectomy in Treatment of Idiopathic Constipation in Children Unknown status NCT02361749 Phase 4 Botulinum Toxin
8 An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study Unknown status NCT03148002 Phase 4 Current Bowel Protocol (senna/lactulose);PEG Bowel Protocol (PEG/lactulose)
9 Effect of Prunes on Gastrointestinal Function After Gynecological Surgery: A Randomized Controlled Trial Unknown status NCT03523715 Phase 4 Docusate Sodium
10 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
11 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
12 A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation Completed NCT00712543 Phase 4 lactulose (Kristalose®);liquid lactulose
13 Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
14 Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation Completed NCT01460225 Phase 4 lubiprostone
15 Non-Inferiority Study; Comparison of Polyethylene Glycol Solution With and Without Electrolytes for Treatment of Chronic Constipation in Elderly Institutionalised Patients: a Double-Blind, Randomised, Parallel-Group, Multicentre Study Completed NCT00603681 Phase 4 Polyethylene glycol 4000;Polyethylene glycol 4000 with electrolytes
16 A Controlled, Randomized, Double-blind Trial to Evaluate the Effect of a Dietary Fiber Mixture During Maintenance Treatment and on Colonic Transit Time in Constipated Pediatric Patients Completed NCT01333787 Phase 4
17 Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial Completed NCT01267370 Phase 4
18 Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease Completed NCT00908076 Phase 4 LUBIPROSTONE
19 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
20 Efficacia Della Fibra di Psyllium Versus Placebo Nella Gestione Dell'Alvo in Pazienti Sottoposti ad Intervento Chirurgico Per Ostruita Defecazione Completed NCT02136693 Phase 4 Psyllium fiber;Placebo
21 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
22 Decreasing Narcotics in Advanced Pelvic Surgery: A Randomized Study Completed NCT02110719 Phase 4 Celebrex;Gabapentin;IV acetaminophen;oral acetaminophen;oral ibuprofen;percocet;vicodin;Oxycodone;dilaudid;Dexamethasone;zofran
23 An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects Completed NCT03279341 Phase 4 polyethylene glycol;Bisacodyl;Prucalopride
24 Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans Completed NCT01500317 Phase 4 Tapentadol;Oxycodone;Placebo
25 Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative Completed NCT01592734 Phase 4 Polyethylene glycol with electrolytes
26 Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial Completed NCT03022201 Phase 4 DA-9701;Domperidone;Placebo domperidone;Placebo DA-9701
27 An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. Completed NCT02590432 Phase 4 Linaclotide
28 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Completed NCT03054805 Phase 4 Magnesium Oxide;MIYAIRI-BM
29 Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications Completed NCT00153127 Phase 4 polyethyleneglycol3350
30 Multicenter, Prospective, Comparative, Randomized Controlled Clinical Trial to Evaluate the Performance and the Safety of Promelaxin® Micro-enemas Vs. Macrogol 4000 Per os in the Treatment of Functional Chronic Constipation in Children Aged Between 6 and 48 Months. Completed NCT02751411 Phase 4 Macrogol 4000
31 Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation Completed NCT00672139 Phase 4 Methylnaltrexone bromide
32 A Prospective, Multicenter, Randomized, Single Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC) Completed NCT04458675 Phase 4 Placebo
33 Investigation of Dried Plums in the Treatment of Adults With Constipation Completed NCT01180725 Phase 4
34 A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
35 A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation Completed NCT01424228 Phase 4 placebo;prucalopride
36 Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation Completed NCT01331213 Phase 4 Pregabalin;Placebo
37 Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
38 A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation. Completed NCT00770432 Phase 4 Polyethylene glycol 3350
39 An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation Completed NCT01707667 Phase 4 prucalopride;PEG 3350
40 Effect of Lactobacillus Reuteri DSM 17938 on Gut Motility in Patients With Functional Constipation Completed NCT01244945 Phase 4
41 A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients Completed NCT01170039 Phase 4 Lubiprostone;Placebo
42 A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC) Completed NCT02228616 Phase 4 Prucalopride;Polyethylene glycol (PEG);Lactulose
43 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management Completed NCT00286520 Phase 4
44 Tolerance of Long Term Administration of Forlax® 10g in Elderly Ambulatory or Institutionalized Patients Suffering From Chronic Constipation. Single Blind Randomised Lactulose-controlled Study With Individual Expected Benefit. Completed NCT00276354 Phase 4 PEG 4000 (Forlax ®)
45 Effectiveness of Lactobacillus Casei Rhamnosus Lcr35 in the Management of Children With Functional Constipation: a Randomized, Double-blind, Placebo- Controlled Trial. Completed NCT01985867 Phase 4
46 A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
47 A Single-arm, Open-label, Multicentre, Non-randomised, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy for the Reversal of Opioid-induced Constipation in Subjects Suffering From Malignant or Non-malignant Pain That Requires Around-the-clock Opioid Therapy Completed NCT01957046 Phase 4 Laxative
48 A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
49 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
50 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

40
Colon, Spinal Cord, Breast, Prostate, Thyroid, Brain, Kidney

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 24840)
# Title Authors PMID Year
1
Acupuncture for chronic constipation in patients with diabetes mellitus: A protocol for systematic review. 61 42
33655948 2021
2
Effect of electroacupuncture treatment on functional constipation in adults: A protocol for systematic review. 61 42
33725843 2021
3
The effect of the therapy of "combination 3 methods progression" in patients with neurogenic bowel dysfunction (constipated type): Study protocol for a randomized controlled trial. 61 42
33607803 2021
4
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
5
Prospect of microbial food borne diseases in Pakistan: a review. 61
33605364 2021
6
Antiviral activity of castor oil plant (Ricinus communis) leaf extracts. 61
33515683 2021
7
Protective effects of curcumin against rat intestinal inflammation‑related motility disorders. 61
33760185 2021
8
Meloxicam for intravenous use: review of its clinical efficacy and safety for management of postoperative pain. 61
33291975 2021
9
High-grade appendiceal mucinous neoplasm presenting as a giant appendiceal mucocele. 61
33680275 2021
10
The synergistic effects of opioid and neuropeptide B/W in rat acute inflammatory and neuropathic pain models. 61
33639195 2021
11
Evaluation of the hepatoprotective activity of Pulicaria incisa subspecies candolleana and in silico screening of its isolated phenolics. 61
33444722 2021
12
Presacral medulloepithelioma with peritoneal carcinomatosis in an 11-year-old boy: An extremely rare association. 61
33747332 2021
13
Seminal vesicles tumor: Rare localization of lymphoma. A case report. 61
33489767 2021
14
Ethnomedicinal uses, phytochemistry, and biological activities of plants of the genus Gynura. 61
33465439 2021
15
Prevalence and predictors of laxatives use in clozapine-related constipation: an observational study. 61
33724255 2021
16
A review of adopted colorectal patients: a parent's perspective. 61
33475771 2021
17
The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. 61
33716293 2021
18
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients. 61
33811502 2021
19
Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. 61
33745570 2021
20
Transvaginal single-port laparoscopic pelvic reconstruction with Y-shaped mesh: experiences of 93 cases. 61
32737533 2021
21
Effect of Kegel exercises on the prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy. 61
33639454 2021
22
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. 61
33566707 2021
23
Recurrent Hypersensitivity to Oral Low-Dose Polyethylene Glycol in a 4-year-old Child with Functional Constipation. 61
33415554 2021
24
Is there a unique symptom in lower urinary tract dysfunction in children? 61
33137854 2021
25
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. 61
33168656 2021
26
Diaphragmatic plication for diaphragmatic eventration caused by chronic constipation: a case report. 61
33454855 2021
27
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. 61
33462925 2021
28
Impact of serotonin transporter gene polymorphism on gut motility in patients with type 2 Diabetes mellitus. 61
33526751 2021
29
Delayed presentation of anorectal malformations in a tertiary care hospital in India. 61
33449157 2021
30
A cohort study analysing outcomes following transanal haemorrhoidal dearterialisation (THD). 61
32223930 2021
31
Varied parameters and utility of the anal position index: a systematic review and meta-analysis. 61
33511448 2021
32
Anorectal manometry in pediatric settings: A systematic review of 227 studies. 61
33118295 2021
33
Prokinetic actions of luminally acting 5-HT4 receptor agonists. 61
33185015 2021
34
[The diagnostic value of hydrogen sulfide breath test for small intestinal bacterial overgrowth]. 61
33765706 2021
35
Early definitive operation for patients with anorectal malformation was associated with a better long-term postoperative bowel function. 61
33492463 2021
36
The Life Cycle of the Mu-Opioid Receptor. 61
33127216 2021
37
Comparison of the chemical constituents of raw Fructus Aurantii and Fructus Aurantii stir-baked with bran, and the biological effects of auraptene. 61
33359001 2021
38
Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome. 61
33797116 2021
39
Rectal mucosal prolapse with an emphasis on endoscopic ultrasound appearance. 61
33478871 2021
40
Patient-centered outcomes used in pediatric focused manual therapies research studies: a secondary data analysis of a systematic review. 61
33796988 2021
41
Impact of clinical pharmacy in oncology and hematology centers: A systematic review. 61
33302824 2021
42
[Use of rapid-onset fentanyl preparations beyond indication : A random questionnaire survey among congress participants and pain physicians]. 61
32975670 2021
43
Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. 61
33135237 2021
44
It Takes a Village: The First 100 Patients Seen in a Multidisciplinary Pelvic Floor Clinic. 61
32371720 2021
45
Efficiency and safety: comparison between preoperative analgesia and postoperative analgesia using non-steroidal anti-inflammatory drugs in patients receiving arthroscopic knee surgery in a multicenter, randomized, controlled study. 61
33797658 2021
46
Effects of Epidural Anesthesia on Quality of Life in Elderly Patients Undergoing Esophagectomy. 61
32805363 2021
47
Coccygodynia Due to a Sacrococcygeal Anomaly: A Rare Cause of Constipation. 61
33105463 2021
48
Abdominal mycotic aortic aneurysm presenting as chronic constipation. 61
33388185 2021
49
NEW PHARMACOLOGIC TREATMENTS FOR IDIOPATHIC CHRONIC CONSTIPATION: A FINANCIAL STRAIN FOR STRAINERS. 61
33798026 2021
50
Konjac glucomannan with probiotics acts as a combination laxative to relieve constipation in mice by increasing short-chain fatty acid metabolism and 5-hydroxytryptamine hormone release. 61
33454530 2021

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter) SNV Pathogenic 523355 rs148292941 GRCh37: 1:161140885-161140885
GRCh38: 1:161171095-161171095
2 COL17A1 NM_000494.4(COL17A1):c.4143_4144AG[1] (p.Glu1382fs) Microsatellite Pathogenic 599000 rs765243124 GRCh37: 10:105793711-105793714
GRCh38: 10:104033953-104033956
3 EBF3 NM_001005463.3(EBF3):c.280_283del (p.Glu94fs) Deletion Pathogenic 375502 rs1057519521 GRCh37: 10:131761639-131761642
GRCh38: 10:129963375-129963378
4 SIL1 NC_000005.10:g.139189727_139201554del Deletion Pathogenic 812923 GRCh37: 5:138525416-138537243
GRCh38:
5 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr) SNV Pathogenic 13919 rs74799832 GRCh37: 10:43617416-43617416
GRCh38: 10:43121968-43121968
6 ARID1B NM_020732.3(ARID1B):c.4110G>A (p.Pro1370=) SNV Uncertain significance 210291 rs797045277 GRCh37: 6:157520041-157520041
GRCh38: 6:157198907-157198907
7 LSM1 NM_014462.3(LSM1):c.231+4A>C SNV Uncertain significance 623485 rs775468919 GRCh37: 8:38027316-38027316
GRCh38: 8:38169798-38169798
8 MT-TT m.15923A>G SNV Uncertain significance 39575 rs1556424691 GRCh37: MT:15923-15923
GRCh38: MT:15923-15923

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 TACR1 SLC6A4 RET OPRM1 KIT HTR4
2 extracellular space GO:0005615 9.81 TAC1 SST SIL1 PYY KIT GDNF
3 axon GO:0030424 9.77 TAC1 RET OPRM1 CCK CALCA
4 extracellular region GO:0005576 9.65 VIP TAC1 SST PYY MLN GDNF
5 perikaryon GO:0043204 9.62 VIP OPRM1 FLNA CCK
6 neuronal cell body GO:0043025 9.1 TAC1 SST RET FLNA CCK CALCA

Biological processes related to Constipation according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 VIP TACR1 RET OPRM1 KIT HTR4
2 response to drug GO:0042493 9.78 SST SLC6A4 RET PPOX
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.67 TACR1 TAC1 OPRM1 CALCA
4 G protein-coupled receptor signaling pathway GO:0007186 9.65 VIP TACR1 TAC1 SST PYY OPRM1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.58 VIP TACR1 OPRM1
6 positive regulation of blood vessel diameter GO:0097755 9.51 VIP CALCA
7 enteric nervous system development GO:0048484 9.46 RET GDNF
8 neuropeptide signaling pathway GO:0007218 9.46 TAC1 PYY OPRM1 CALCA
9 tachykinin receptor signaling pathway GO:0007217 9.43 TACR1 TAC1
10 regulation of sensory perception of pain GO:0051930 9.43 VIP OPRM1 CCK
11 detection of abiotic stimulus GO:0009582 9.32 TACR1 TAC1
12 response to pain GO:0048265 8.92 TACR1 TAC1 RET CALCA

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.26 SLC6A4 HTR4
2 peptide hormone receptor binding GO:0051428 9.16 VIP CCK
3 neuropeptide hormone activity GO:0005184 9.13 VIP PYY CCK
4 hormone activity GO:0005179 9.1 VIP SST PYY MLN CCK CALCA

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....